Cargando…

Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to more than 150 million infections and about 3.1 million deaths up to date. Currently, drugs screened are urgently aiming to block the infection of SARS-CoV-2. Here, we explo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Fang, Mu, Chenglin, Kwok, Hang Fai, Xu, Jiyuan, Wu, Yingliang, Liu, Wanhong, Sabatier, Jean-Marc, Annweiler, Cédric, Li, Xugang, Cao, Zhijian, Xie, Yingqiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241724/
https://www.ncbi.nlm.nih.gov/pubmed/34239361
http://dx.doi.org/10.7150/ijbs.57810
_version_ 1783715474187485184
author Sun, Fang
Mu, Chenglin
Kwok, Hang Fai
Xu, Jiyuan
Wu, Yingliang
Liu, Wanhong
Sabatier, Jean-Marc
Annweiler, Cédric
Li, Xugang
Cao, Zhijian
Xie, Yingqiu
author_facet Sun, Fang
Mu, Chenglin
Kwok, Hang Fai
Xu, Jiyuan
Wu, Yingliang
Liu, Wanhong
Sabatier, Jean-Marc
Annweiler, Cédric
Li, Xugang
Cao, Zhijian
Xie, Yingqiu
author_sort Sun, Fang
collection PubMed
description Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to more than 150 million infections and about 3.1 million deaths up to date. Currently, drugs screened are urgently aiming to block the infection of SARS-CoV-2. Here, we explored the interaction networks of kinase and COVID-19 crosstalk, and identified phosphoinositide 3-kinase (PI3K)/AKT pathway as the most important kinase signal pathway involving COVID-19. Further, we found a PI3K/AKT signal pathway inhibitor capivasertib restricted the entry of SARS-CoV-2 into cells under non-cytotoxic concentrations. Lastly, the signal axis PI3K/AKT/FYVE finger-containing phosphoinositide kinase (PIKfyve)/PtdIns(3,5)P2 was revealed to play a key role during the cellular entry of viruses including SARS-CoV-2, possibly providing potential antiviral targets. Altogether, our study suggests that the PI3K/AKT kinase inhibitor drugs may be a promising anti-SARS-CoV-2 strategy for clinical application, especially for managing cancer patients with COVID-19 in the pandemic era.
format Online
Article
Text
id pubmed-8241724
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-82417242021-07-07 Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19 Sun, Fang Mu, Chenglin Kwok, Hang Fai Xu, Jiyuan Wu, Yingliang Liu, Wanhong Sabatier, Jean-Marc Annweiler, Cédric Li, Xugang Cao, Zhijian Xie, Yingqiu Int J Biol Sci Research Paper Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to more than 150 million infections and about 3.1 million deaths up to date. Currently, drugs screened are urgently aiming to block the infection of SARS-CoV-2. Here, we explored the interaction networks of kinase and COVID-19 crosstalk, and identified phosphoinositide 3-kinase (PI3K)/AKT pathway as the most important kinase signal pathway involving COVID-19. Further, we found a PI3K/AKT signal pathway inhibitor capivasertib restricted the entry of SARS-CoV-2 into cells under non-cytotoxic concentrations. Lastly, the signal axis PI3K/AKT/FYVE finger-containing phosphoinositide kinase (PIKfyve)/PtdIns(3,5)P2 was revealed to play a key role during the cellular entry of viruses including SARS-CoV-2, possibly providing potential antiviral targets. Altogether, our study suggests that the PI3K/AKT kinase inhibitor drugs may be a promising anti-SARS-CoV-2 strategy for clinical application, especially for managing cancer patients with COVID-19 in the pandemic era. Ivyspring International Publisher 2021-06-11 /pmc/articles/PMC8241724/ /pubmed/34239361 http://dx.doi.org/10.7150/ijbs.57810 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Sun, Fang
Mu, Chenglin
Kwok, Hang Fai
Xu, Jiyuan
Wu, Yingliang
Liu, Wanhong
Sabatier, Jean-Marc
Annweiler, Cédric
Li, Xugang
Cao, Zhijian
Xie, Yingqiu
Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19
title Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19
title_full Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19
title_fullStr Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19
title_full_unstemmed Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19
title_short Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19
title_sort capivasertib restricts sars-cov-2 cellular entry: a potential clinical application for covid-19
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241724/
https://www.ncbi.nlm.nih.gov/pubmed/34239361
http://dx.doi.org/10.7150/ijbs.57810
work_keys_str_mv AT sunfang capivasertibrestrictssarscov2cellularentryapotentialclinicalapplicationforcovid19
AT muchenglin capivasertibrestrictssarscov2cellularentryapotentialclinicalapplicationforcovid19
AT kwokhangfai capivasertibrestrictssarscov2cellularentryapotentialclinicalapplicationforcovid19
AT xujiyuan capivasertibrestrictssarscov2cellularentryapotentialclinicalapplicationforcovid19
AT wuyingliang capivasertibrestrictssarscov2cellularentryapotentialclinicalapplicationforcovid19
AT liuwanhong capivasertibrestrictssarscov2cellularentryapotentialclinicalapplicationforcovid19
AT sabatierjeanmarc capivasertibrestrictssarscov2cellularentryapotentialclinicalapplicationforcovid19
AT annweilercedric capivasertibrestrictssarscov2cellularentryapotentialclinicalapplicationforcovid19
AT lixugang capivasertibrestrictssarscov2cellularentryapotentialclinicalapplicationforcovid19
AT caozhijian capivasertibrestrictssarscov2cellularentryapotentialclinicalapplicationforcovid19
AT xieyingqiu capivasertibrestrictssarscov2cellularentryapotentialclinicalapplicationforcovid19